|
|
Journal of Zhejiang University SCIENCE B
ISSN 1673-1581(Print), 1862-1783(Online), Monthly
2019 Vol.20 No.7 P.598-604
Relationship between genetic variation in the α2A-adrenergic receptor and the cardiovascular effects of dexmedetomidine in the Chinese Han population
Abstract: There are differences in individual cardiovascular responses to the administration of dexmedetomidine, a highly selective α2A-adrenergic receptor (ADRA2A) agonist. The aim of this study was to investigate ADRA2A gene polymorphisms in the Chinese Han population and their association with the cardiovascular response to intravenous dexmedetomidine infusion. Sixty elective surgery patients of Chinese Han nationality were administered 1 µg/kg dexmedetomidine intravenously over 10 min as a premedication. ADRA2A C-1291G and A1780G polymorphism status was determined in these patients, and their relationships to changes in blood pressure and heart rate after dexmedetomidine administration were analyzed. There were neither significant differences in systolic or diastolic blood pressure changes in individuals with different A1780G and C-1291G genotypes after dexmedetomidine administration, nor in heart rates among the different A1780G genotypes. However, there were significant differences in changes in heart rates in patients with different C-1291G genotypes. There were no significant differences in the sedative effects of dexmedetomidine among different A1780G and C-1291G genotypes. Logistic regression revealed that the C-1291G polymorphism was associated with differential decreases in heart rate after intravenous infusion of dexmedetomidine. These findings indicate that the ADRA2A C-1291G polymorphism can affect heart rate changes in patients after intravenous infusion of dexmedetomidine.
Key words: Dexmedetomidine; α2A-Adrenergic receptor; Polymorphism; Blood pressure; Heart rate
Chinese Summary <20> 中国汉族人群中肾上腺素α2A受体基因多态性与右美托咪定心血管效应的相关性研究
关键词组：
References:
[1]Galley HF, Mahdy A, Lowes DA, 2005. Pharmacogenetics and anesthesiologists. Pharmacogenomics, 6(8):849-856.
[2]Ice CJ, Personett HA, Frazee EN, et al., 2016. Risk factors for dexmedetomidine-associated hemodynamic instability in noncardiac intensive care unit patients. Anesth Analg, 122(2):462-469.
[3]Kohli U, Muszkat M, Sofowora GG, et al., 2010. Effects of variation in the human α2A- and α2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain, 14(2):154-159.
[4]Kohli U, Pandharipande P, Muszkat M, et al., 2012. CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol, 68(6):937-942.
[5]Kurnik D, Muszkat M, Li C, et al., 2006. Variations in the α2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther, 79(3):173-185.
[6]Kurnik D, Muszkat M, Sofowora GG, et al., 2008. Ethnic and genetic determinants of cardiovascular response to the selective α2-adrenoceptor agonist dexmedetomidine. Hypertension, 51(2):406-411.
[7]Kurnik D, Muszkat M, Li C, et al., 2011. Genetic variations in the α2A-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. Circ Cardiovasc Genet, 4(2):179-187.
[8]Li TJ, Zhu XL, Wu XP, et al., 2012. Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population. Genet Test Mol Biomarkers, 16(12):1424-1427.
[9]Lima JJ, Feng H, Duckworth L, et al., 2007. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism, 56(6):757-765.
[10]Madsen O, Willemsen D, Ursing BM, et al., 2002. Molecular evolution of the mammalian alpha 2B adrenergic receptor. Mol Biol Evol, 19(12):2150-2160.
[11]Mantz J, Josserand J, Hamada S, 2011. Dexmedetomidine: new insights. Eur J Anaesthesiol, 28(1):3-6.
[12]Neema PK, 2012. Dexmedetomidine in pediatric cardiac anesthesia. Ann Card Anaesth, 15(3):177-179.
[13]Paliwal B, Rai P, Kamal M, et al., 2015. Comparison between dexmedetomidine and propofol with validation of bispectral index for sedation in mechanically ventilated intensive care patients. J Clin Diagn Res, 9(7):UC01-UC05.
[14]Small KM, Brown KM, Seman CA, et al., 2006. Complex haplotypes derived from noncoding polymorphisms of the intronless α2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci USA, 103(14):5472-5477.
[15]Talke P, Lobo E, Brown R, 2003. Systemically administered α2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology, 99(1):65-70.
[16]Talke P, Stapelfeldt C, Lobo E, et al., 2005. Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction. Pharmacogenet Genomics, 15(5):357-363.
[17]Yağar S, Yavas S, Karahalil B, 2011. The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep, 38(5):3383-3389.
[18]Yin L, Zhang X, Huang Y, et al., 2016. Catecholamine pathway polymorphisms and antidepressant response. Asia Pac Psychiatry, 8(2):109-117.
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.B1800647
CLC number:
R614.2
Download Full Text:
Downloaded:
2063
Download summary:
<Click Here>Downloaded:
1532Clicked:
3513
Cited:
0
On-line Access:
2019-06-06
Received:
2018-12-31
Revision Accepted:
2019-03-26
Crosschecked:
2019-05-23
Tel: +86-571-87952276; Fax: +86-571-87952331; E-mail: jzus@zju.edu.cn
Copyright © 2000~ Journal of Zhejiang University-SCIENCE